Steve Gelone Joins Kineticos as a Strategic Advisor for Kineticos AMR Accelerator Fund I (KAMRA I)
Raleigh, North Carolina – February 7, 2025 – Kineticos Life Sciences is pleased to announce that Steve Gelone, Pharm.D., has joined as a Strategic Advisor for the Kineticos AMR Accelerator Fund I (KAMRA I). A highly accomplished biopharmaceutical executive with over 25 years of experience in drug development, company formation, and capital raising, Dr. Gelone will play a pivotal role in advancing Kineticos’ mission of A World Without Antimicrobial Resistance™.
Dr. Gelone currently serves as President and Chief Executive Officer of Hula Therapeutics, an immuno-oncology spinout from the Children’s Hospital of Philadelphia. His extensive leadership experience, spanning multiple biotech companies, makes him a valuable addition to KAMRA I as the fund continues to invest in transformative solutions targeting antimicrobial resistance (AMR).
“I’m excited to welcome Dr. Gelone as a Strategic Advisor for the Kineticos AMR Accelerator Fund. Steve has been instrumental in getting breakthrough products approved in the fight against antimicrobial resistance. His proven expertise and leadership in navigating complex regulatory pathways will be invaluable as we continue to advance transformative healthcare solutions. I look forward to leveraging his insights to drive innovation and impact across our portfolio,” said Shailesh Maingi, Founder and Managing Partner of Kineticos.
Prior to his role at Hula Therapeutics, Dr. Gelone held key leadership positions at ViroPharma Incorporated, Spark Therapeutics, Nabriva Therapeutics, Convergence Bio, and Kinvard Bio. Over the course of his career, he has played an integral role in securing eight NDA or BLA approvals and has been instrumental in raising over $750 million across private and public markets, including two successful IPOs.
With a background in infectious diseases and drug development, Dr. Gelone began his career as a tenured professor at Temple University Schools of Pharmacy and Medicine in the Division of Infectious Diseases. His extensive experience in both academic and industry settings positions him uniquely to support KAMRA I portfolio companies in their mission to combat AMR.
“Infectious diseases remain one of the greatest threats to human health,” said Dr. Gelone. “The availability of safe and highly effective anti-infective agents has been the cornerstone enabling every major medical advance in modern history. Continued investment in the discovery and development of antibacterial agents is critical to maintaining a thriving ecosystem that will deliver the next generation of anti-infectives. I am delighted to work with the Kineticos team on this mission to advance innovative science and ensure the future of public health.”
KAMRA I is dedicated to addressing the urgent challenge of antimicrobial resistance by investing in and supporting companies developing novel anti-infective therapies. Through a combination of deep sector expertise, strategic partnerships, and hands-on company-building, KAMRA I is committed to driving innovation and transforming the anti-infectives landscape.
About Kineticos
Kineticos Life Sciences (Kineticos) envisions a world without antimicrobial resistance, cancer, and rare and neurodegenerative diseases. We are entrepreneurs helping entrepreneurs build companies to improve patient outcomes. Kineticos leverages our expertise, network, ecosystem, and capital to provide the most relevant insights and recommendations for our portfolio companies, building value every step of the way. Kineticos began investing in 2019 and through its investment vehicles has invested more than $75M across 13 companies, as of September 30, 2024.
Contact: investorrelations@kineticos.com
www.kineticos.com
Linkedin:@Kineticos